Ginette Santiago, Postdoctoral Research Fellow at National Cancer Institute (NCI), shared a post on LinkedIn:
“Proud to share our latest publication!
Our study showed, for the first time, that combination therapy with olaparib plus mSTAR1302 (the murine surrogate for Invikafusp alfa) elicited significant regression and survival benefit in two immune-excluded murine prostate cancer models. The antitumor response was associated with (1) a decrease in immunosuppressive cells, (2) an increase in activated Vβ13+ CD4+ and Vβ13+ CD8+ T cells, and (3) an increase in the progenitor-exhausted CD8+ T cell population. TRAIL-R2 upregulation modulated by olaparib is critical for the antitumor efficacy elicited by combination therapy with olaparib plus mSTAR1302.
The ongoing phase 2 clinical trial evaluating STAR0602, Marengo’s first-in-class selective dual T cell agonist, demonstrated expanded pan-tumor single-agent activity.
Our study provides rationale supporting the design of a clinical trial evaluating the combination of olaparib plus STAR0602 for patients with mCRPC who have progressed on androgen deprivation therapy.”
Title: PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression
Authors: Ginette Santiago-Sanchez, Francesca Rosato, Kellsye P. Fabian, Michelle R. Padget, Jung-Min Lee, Fatima Karzai, Jeffrey Schlom, James L. Gulley, Duane H. Hamilton, Jonelle K. Lee, Margaret R. Pruitt, Andrew Bayliffe, Zhen Su, Jacques Moisan, Madan Katragadda, James W. Hodge
Read the Full Article.
